Treasury Draft Rules Would Restrict U.S. Investments in China's Biotech Sector
Treasury's draft outbound investment regulations would extend prohibitions to certain U.S. investments in China's biotechnology sector, pulling fund commitments, joint ventures and licensing deals into scope ahead of a final rule.
Jones Day reports that the U.S. Treasury Department has issued draft regulations that would prohibit certain U.S. investments into China's biotechnology sector, extending the outbound investment security program into an additional technology field. The regime's existing covered sectors — semiconductors, quantum information and artificial intelligence, among others — would gain biotechnology, and with it new prohibitions or restrictions on covered transactions by covered U.S. persons, which in practice reaches private equity, venture capital and corporate investment activity rather than only strategic deals.
For sophisticated clients the question is not only whether a specific financing is captured, but whether pending fund commitments, joint ventures, licensing or co-development arrangements with China-linked counterparties would need clearance or fall inside a prohibited category once final rules issue. Because this is a draft, the operational variables that determine exposure — sector definitions, thresholds, carve-outs, covered transaction forms and the effective date — are unresolved, and the alert does not state the comment period or any transaction-level exceptions.
Two concrete next steps: watch for the draft's publication in the Federal Register and the comment deadline, then the final rule's effective date; and start screening existing China biotech exposure now, since diligence on funds and license flows takes longer than the rulemaking will.